| Literature DB >> 34992354 |
Molalign Tarekegn Minwagaw1, Betelihem Belete Akenie1, Desalew Salew Tewabe1, Awoke Seyoum Tegegne2, Tariku Belachew Beyene3.
Abstract
BACKGROUND: Globally, HIV/AIDS has challenged the lives of 36.3 million people and resulted in 17 million orphans. The disease has neither a vaccine nor a cure and the only option currently is highly active antiretroviral therapy. This research was conducted to identify the predictors of poor adherence to CART and treatment failure at second-line regimen among adults living with HIV/AIDS in public hospitals of Amhara region, north-western Ethiopia.Entities:
Keywords: HIV/AIDS; adherence; bivariate data analysis; second-line regimens; treatment failure
Year: 2021 PMID: 34992354 PMCID: PMC8713999 DOI: 10.2147/PPA.S339108
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1Conceptual framework between response and predictor variables in second-line regimens.
Baseline Characteristics of Participants (n = 700), Socio-Demographic Variables
| Variables | Categories | F | % |
|---|---|---|---|
| Sex | Female | 375 | 53.57 |
| Male | 325 | 46.43 | |
| Marital status | Living with Partner | 318 | 45.43 |
| Living without partner | 380 | 54.57 | |
| Level of education | Illiterate | 220 | 31.43 |
| Literate | 480 | 68.57 | |
| Religion | Orthodox Christian | 591 | 84.43 |
| Muslim | 106 | 15.14 | |
| Others | 3 | 0.29 | |
| Residence | Rural | 159 | 22.71 |
| Urban | 541 | 77.29 | |
| Partner HIV status | Negative | 81 | 11.57 |
| Not Applicable | 139 | 19.86 | |
| Positive | 230 | 32.86 | |
| Unknown | 250 | 35.71 | |
| Functional Status | Ambulatory | 107 | 15.29 |
| Bed ridden | 23 | 3.29 | |
| Working | 570 | 81.43 | |
| OI’s at the time of switch to 2nd line | No | 573 | 81.97 |
| Yes | 106 | 18.03 | |
| TB at the time of switch | Yes | 41 | 5.8 |
| No | 659 | 94.2 | |
| HBV status at the time of switch to 2nd line | Negative | 88 | 12.57 |
| Not Done | 606 | 86.57 | |
| Positive | 6 | 0.86 | |
| Other chronic disease | No | 668 | 95.43 |
| Yes | 32 | 4.57 | |
| History of depression while on 2nd line | No | 673 | 96.14 |
| Yes | 27 | 3.86 | |
| Pregnancy during 2nd line regimen | No | 314 | 44.86 |
| Not Applicable | 359 | 51.29 | |
| Yes | 27 | 3.86 |
Baseline Characteristics of Participants (n = 700), Clinical Variables
| Variables | Categories | F | % |
|---|---|---|---|
| WHO clinical stage at switch to 2nd line | 1 | 521 | 74.43 |
| 2 | 47 | 6.71 | |
| 3 | 92 | 13.14 | |
| 4 | 40 | 5.71 | |
| CD4 Count CD4 below 100 | No | 572 | 81.71 |
| Yes | 128 | 18.29 | |
| Acute nutritional problem | No | 592 | 84.57 |
| Yes | 108 | 15.43 | |
| Drug toxicity | No | 679 | 97 |
| Yes | 21 | 3 | |
| Disclosure Status | Disclosed | 676 | 96.57 |
| Not Disclosed | 24 | 3.43 | |
| NRTI backbone at switch | ABC+3TC | 87 | 12.4 |
| AZT+3TC | 249 | 35.4 | |
| TDF+3TC | 368 | 52.3 | |
| PI/NNRTI | ATV/r | 629 | 89.3 |
| AZT/r based | 5 | 0.7 | |
| EFV based | 9 | 1.3 | |
| Kaletra based | 4 | 0.6 | |
| LPV/r based | 45 | 6.5 | |
| NVP based | 11 | 1.6 | |
| Adherence to HAART | Adherent | 275 | 39.3 |
| Non-adherent | 425 | 60.7 | |
| Treatment output at second line regimens | Success | 287 | 41 |
| Failure | 413 | 59 |
Covariance Structure Under Current Investigation
| Covariance Structure | Information Criteria | ||
|---|---|---|---|
| AIC | BIC | Log Lik | |
| AR (1) | 16,594.9 | 16,791.4 | −7316.3 |
| TOEP | 16875.0 | 17,251.4 | −7563.2 |
| UN | 16523.3 | 16,631.7 | −7265.9 |
| CS | 16647.7 | 16,892.4 | −7739.6 |
Multivariate Regression Analysis for Adherence to HAART and Treatment Failure Using Maximum Likelihood Estimation
| Parameter | Poor Adherence | Treatment Failure | ||||
|---|---|---|---|---|---|---|
| Estimates | St. Error | p-value | Estimates | St. Error | p-value | |
| Intercept | 3.014 | 0.003 | <0.01* | 0.922 | 0.245 | <0.001* |
| Age | 0.025 | 0.011 | 0.003* | 0.122 | 0.013 | < 0.001* |
| Weight | −0.021 | 0.014 | 0.061 | 0.031 | 0.016 | 0.073 |
| Baseline CD4 cell count | −0.014 | 0.013 | <0.001* | −0.022 | 0.014 | <0.001* |
| Number of follow-ups | −0.032 | 0.043 | <0.001* | −0.033 | 0.038 | 0.012* |
| Marital status (Ref. =Without partner) | ||||||
| With partners | −0.023 | 0.035 | 0.053 | −0.012 | 0.051 | 0.061 |
| Sex (Ref.=Male | ||||||
| Female | −0.010 | 0.016 | <0.001 | −0.014 | 0.104 | < 0.001* |
| Partner HIV status (Reference=Positive) | ||||||
| Negative | −0.021 | 0.542 | < 0.001 | −0.012 | 0.231 | < 0.001* |
| Existence of social discrimination (Ref.=yes) | ||||||
| No | 0.046 | 0.435 | <0.001 | −0.132 | 0.023 | 0.002* |
| Special support for patients disclosed disease (Ref.=yes) | ||||||
| No | −0.031 | 0.763 | 0.002 | −0.031 | 0.231 | 0.031* |
| History of depression while on 2nd line (Ref.=yes) | ||||||
| No | 0.021 | 0.923 | 0.013 | 0.021 | 0.231 | 0.003* |
| Residence area (Ref.=Urban) | ||||||
| Rural | 0.015 | 0.016 | 0.045* | 0.134 | 0.013 | 0.014* |
| Level of education (Ref.=Literate) | ||||||
| Illiterate | 0.026 | 0.015 | <0.012* | 0.125 | 0.154 | 0.012* |
| Opportunistic infectious disease at the time of switch to second line regimens (Ref.=no) | ||||||
| Yes | 0.034 | 0.204 | <0.013* | 0.125 | 0.091 | < 0.013* |
| Functional Status (Ref.=working status) | ||||||
| Bed-ridden | 0.051 | 0.342 | 0.023* | 0.024 | 0.453 | 0.021* |
| Ambulatory | 0.034 | 0.241 | <0.001* | 0.031 | 0.621 | <0.001* |
| WHO stages (Ref.=stage IV) | ||||||
| Stage I | −0.137 | 0.015 | <0.014* | −0.192 | 0.013 | 0.072 |
| Stage II | −0.146 | 0.016 | <0.061 | −0.246 | 0.094 | 0.055 |
| Stage III | −0.104 | 0.014 | <0.015* | −0.116 | 0.092 | 0.092 |
| Acute malnutrition (Ref.=yes) | ||||||
| No | −0.124 | 0.014 | <0.015* | −0.135 | 0.092 | 0.012* |
| Drug toxicity (ref.=yes) | ||||||
| No | −0.004 | 0.034 | 0.015* | −0.156 | 0.092 | 0.092 |
| CD4 cell Count | −0.124 | 0.014 | 0.025* | −0.156 | 0.092 | 0.032* |
Note: *Stands for statistical significant predictor.